ClinicalTrials.gg
TerminatedNCT01496430Updated May 6, 2015Results posted

Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

A Phase 3 interventional study of Placebo and Azilsartan medoxomil in Hypertension and Diabetes, sponsored by Takeda. Terminated at 68 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-06.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Why this study was terminated
Business Decision; No Safety Or Efficacy Concerns. (See below)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.

Enrollment
18th of 21
105 · median 566
Started
2012
the only one that year
Phase 3
17 of 21
none open now
Registered
18th of 21
by date
Lead sponsor
19 of 21
Takeda

Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 18th largest by enrollment, is the only one that started in 2012, is one of 17 in phase 3, and was the 18th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing azilsartan medoxomil in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus (T2DM) participants whose glycemic control was inadequate on metformin alone.

Read the detailed description

The study included a Screening Period of up to 4 weeks, which coincided with a 2-week single-blind, placebo Run-in Period, a 24 week Treatment Period, and a 2-week Follow-up Period. The duration of the study was approximately 30 weeks. The planned number of participants (n=450) was not reached; actual enrollment consisted of 105 particpants. Due to low enrollment this study was terminated early by Takeda.

03

Conditions studied

  • Hypertension
  • Diabetes

Keywords

  • Drug Therapy
  • Hypertension and Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Was male or female and ≥18 years.
  2. Had type 2 diabetes mellitus with of ≥7.5 to ≤9.5% at Screening.
  3. Was treated with metformin alone (no treatment with any antidiabetic agents other than metformin within the 3 months prior to Screening) and was experiencing inadequate glycemic control. The participant should have received metformin monotherapy for ≥8 weeks prior to Screening at a stable dose ≥1500 mg). Participants with a maximum tolerated dose (MTD) that was documented to be less than 1500 mg of metformin could also be enrolled if this dose had been stable for 8 weeks prior to Screening.
  4. Was treated with antihypertensive therapy and had a mean, trough, sitting clinic systolic blood pressure (SBP) ≥135 and \< 160 mm Hg on Day -1 (after washout of prior antihypertensive therapy) or the participant had not received antihypertensive treatment within 28 days before Screening and had a mean sitting clinic SBP ≥135 and \< 160 mm Hg at the Screening Visit and on Day -1.
  5. Had clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or results that were deemed not in this participant population for inclusion in this study, by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Had a mean, trough, sitting clinic diastolic blood pressure (DBP) ≥ 100 mm Hg at Day -1.
  2. Had type 1 or poorly controlled type 2 diabetes mellitus ( >9.5%) at Screening.
  3. Was taking or expected to take an excluded medication.
  4. Had a history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or .
  5. Had cardiac conduction defects (for example, 3rd degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation).
  6. Had hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  7. Had secondary hypertension of any etiology (e.g., renovascular disease, pheochromocytoma, Cushing's syndrome).
  8. Had renal dysfunction defined as estimated (eGFR) \<60 mL/min/1.73 m2 at Screening.
  9. Had albuminuria defined as >200 mg/g at Screening.
  10. Had known or suspected unilateral or bilateral renal artery stenosis.
  11. Had unexplained microhematuria ≥3 RBCs/HPF or macrohematuria at Screening and confirmed on repeat testing.
  12. Treatment with antidiabetic agents (sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides, thiazolidinediones (TZDs), and/or insulin) other than metformin during the 3 months prior to Screening.
  13. Had hyperkalemia as defined by central laboratory normal reference range at Screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Placebo comparator
    Placebo QD

    Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.

    Drug: Placebo

  • Experimental
    Azilsartan Medoxomil 40 mg QD

    Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.

    Drug: Azilsartan medoxomil

  • Experimental
    Azilsartan Medoxomil 80 mg QD

    Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.

    Drug: Azilsartan medoxomil

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure

    The change in trough systolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c)

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure

    The change in trough diastolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.

    Time frame: Baseline and Week 8

  3. Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 8

  4. Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline and Week 8

  5. Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in daytime (6am to 10pm) mean systolic blood pressure measured week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 8

  6. Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

    Time frame: Baseline and Week 8

  7. Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 8

  8. Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

    Time frame: Baseline and Week 8

  9. Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.

    Time frame: Baseline and Week 8

  10. Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.

    Time frame: Baseline and Week 8

  11. Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

    The change in trough systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8

  12. Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

    The change in trough diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline and Week 8

  13. Percentage of Participants Requiring Rescue Glycemic Therapy

    Percentage of participants requiring rescue glycemic therapy during study.

    Time frame: 24 Weeks

  14. Time to First Glycemic Rescue

    The time to the first instance of participants requiring glycemic rescue during study.

    Time frame: 24 Weeks

  15. Change From Baseline in HbA1c

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.

    Time frame: Baseline and Weeks 2, 4, 6, 8, 12, 16 and 20

  16. Change From Baseline in Fasting Plasma Glucose

    The change between the fasting plasma glucose value collected at each week indicated relative to baseline.

    Time frame: Baseline and Weeks 2, 4, 6, 8, 12, 16, 20, and 24

  17. Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)

    The change between the glucose value collected at weeks 6 and 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

    Time frame: Baseline and Weeks 6 and 24

  18. Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT

    The change between the AUC for glucose at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

    Time frame: Baseline and Weeks 6 and 24

  19. Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT

    The change between the AUC for insulin at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

    Time frame: Baseline and Weeks 6 and 24

  20. Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT

    The change between the AUC for C-peptide at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

    Time frame: Baseline and Weeks 6 and 24

  21. Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT

    The change between the AUC for insulin/glucose ratio at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

    Time frame: Baseline and Weeks 6 and 24

  22. Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT

    The change between the AUC for glucagon at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

    Time frame: Baseline and Weeks 6 and 24

07

Results

Posted May 6, 2015
Limitations and caveats
Because of low enrollment in the study, the sample sizes in the results data do not allow for significant interpretation of the results.

Participant flow

Participants took part in the study at 41 investigative sites in the United States from 09 January 2012 to 30 May 2013.

Participant flow — Overall Study
MilestonePlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Started353535
Completed293025
Not completed6510
Withdrew: Adverse event001
Withdrew: Major protocol deviation001
Withdrew: Lost to follow-up231
Withdrew: Voluntary withdrawal216
Withdrew: Principal investigator discretion011
Withdrew: Other200

Outcome measures

PrimaryChange From Baseline in Trough Sitting Clinic Systolic Blood Pressure

The change in trough systolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure-3.1 ± 2.71-10.2 ± 2.69-13.6 ± 2.70
Statistical analysis
  • Placebo QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = 0.007 (Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.)
  • Placebo QD vs Azilsartan Medoxomil 40 mg QD · ANCOVA · p = 0.067 (Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.)
SecondaryChange From Baseline in Glycosylated Hemoglobin (HbA1c)

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · percentage glycosylated hemoglobin
Change From Baseline in Glycosylated Hemoglobin (HbA1c)
percentage glycosylated hemoglobinPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in Glycosylated Hemoglobin (HbA1c)0.12 ± 0.174-0.19 ± 0.1740.07 ± 0.179
Statistical analysis
  • Placebo QD vs Azilsartan Medoxomil 80 mg QD · ANCOVA · p = 0.860 (Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.)
  • Placebo QD vs Azilsartan Medoxomil 40 mg QD · ANCOVA · p = 0.210 (Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.)
SecondaryChange From Baseline in Trough Sitting Clinic Diastolic Blood Pressure

The change in trough diastolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure-0.8 ± 1.36-5.4 ± 1.37-5.8 ± 1.37
SecondaryChange From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring-1.6 ± 2.25-8.3 ± 2.15-11.3 ± 2.31
SecondaryChange From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring-1.0 ± 1.28-4.7 ± 1.22-7.2 ± 1.31
SecondaryChange From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in daytime (6am to 10pm) mean systolic blood pressure measured week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring-2.0 ± 2.23-9.0 ± 2.13-11.7 ± 2.28
SecondaryChange From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring-1.4 ± 1.25-5.1 ± 1.20-7.5 ± 1.28
SecondaryChange From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring0.4 ± 2.68-6.2 ± 2.57-10.9 ± 2.76
SecondaryChange From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring0.6 ± 1.65-3.2 ± 1.58-7.2 ± 1.69
SecondaryChange From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring-2.7 ± 2.40-8.6 ± 2.29-12.3 ± 2.45
SecondaryChange From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring-1.9 ± 1.37-4.7 ± 1.31-8.2 ± 1.40
SecondaryChange From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

The change in trough systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring2.3 ± 2.80-7.6 ± 2.67-7.9 ± 2.87
SecondaryChange From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

The change in trough diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · mm Hg
Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring
mm HgPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring0.2 ± 1.63-6.8 ± 1.57-4.0 ± 1.66
SecondaryPercentage of Participants Requiring Rescue Glycemic Therapy

Percentage of participants requiring rescue glycemic therapy during study.

Time frame:
24 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Rescue Glycemic Therapy
percentage of participantsPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Percentage of Participants Requiring Rescue Glycemic Therapy25.725.725.7
SecondaryTime to First Glycemic Rescue

The time to the first instance of participants requiring glycemic rescue during study.

Time frame:
24 Weeks
Reported as:
Median · Days
Time to First Glycemic Rescue
DaysPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Time to First Glycemic RescueNA (21.57 to NA)NA (22.57 to NA)NA (17.14 to NA)
SecondaryChange From Baseline in HbA1c

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.

Time frame:
Baseline and Weeks 2, 4, 6, 8, 12, 16 and 20
Reported as:
Least squares mean · percentage glycosylated hemoglobin
Change From Baseline in HbA1c
percentage glycosylated hemoglobinPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Week 2 (n=34, 35, 32)-0.01 ± 0.0720.05 ± 0.071-0.06 ± 0.074
Week 4 (n=35, 35, 33)-0.02 ± 0.093-0.02 ± 0.0930.29 ± 0.096
Week 6 (n=35, 35, 33)0.06 ± 0.123-0.02 ± 0.1230.24 ± 0.127
Week 8 (n=35, 35, 33)0.05 ± 0.137-0.03 ± 0.1380.23 ± 0.141
Week 12 (n=35, 35, 33)0.00 ± 0.171-0.05 ± 0.1710.29 ± 0.176
Week 16 (n=35, 35, 33)0.09 ± 0.171-0.06 ± 0.1710.16 ± 0.176
Week 20 (n=35, 35, 33)0.14 ± 0.167-0.13 ± 0.1680.09 ± 0.172
SecondaryChange From Baseline in Fasting Plasma Glucose

The change between the fasting plasma glucose value collected at each week indicated relative to baseline.

Time frame:
Baseline and Weeks 2, 4, 6, 8, 12, 16, 20, and 24
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose
mmol/LPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Week 2 (n=34, 35, 34)0.16 ± 0.4350.64 ± 0.4291.03 ± 0.435
Week 4 (n=35, 35, 34)0.96 ± 0.4640.45 ± 0.4640.81 ± 0.470
Week 6 (n=35, 35, 34)0.71 ± 0.4450.28 ± 0.4450.81 ± 0.451
Week 8 (n=35, 35, 34)0.39 ± 0.3680.34 ± 0.3680.96 ± 0.373
Week 12 (n=35, 35, 34)0.76 ± 0.4170.09 ± 0.4170.94 ± 0.423
Week 16 (n=35, 35, 34)0.36 ± 0.3790.17 ± 0.3790.49 ± 0.384
Week 20 (n=35, 35, 34)0.94 ± 0.4380.01 ± 0.4380.86 ± 0.444
Week 24 (n=35, 35, 34)0.76 ± 0.459-0.15 ± 0.4590.48 ± 0.465
SecondaryChange From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)

The change between the glucose value collected at weeks 6 and 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

Time frame:
Baseline and Weeks 6 and 24
Reported as:
Least squares mean · mmol/L
Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)
mmol/LPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Week 6 (n=30, 30, 29)1.01 ± 0.555-0.46 ± 0.556-0.09 ± 0.565
Week 24 (n=25, 26, 19)-0.44 ± 0.824-1.66 ± 0.811-3.94 ± 0.949
SecondaryChange From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT

The change between the AUC for glucose at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

Time frame:
Baseline and Weeks 6 and 24
Reported as:
Least squares mean · mmol*hours/L
Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT
mmol*hours/LPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Week 6 (n=28, 29, 29)1.60 ± 1.159-1.01 ± 1.1481.04 ± 1.140
Week 24 (n=23, 24, 19)-1.97 ± 1.339-1.13 ± 1.308-5.52 ± 1.471
SecondaryChange From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT

The change between the AUC for insulin at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

Time frame:
Baseline and Weeks 6 and 24
Reported as:
Least squares mean · pmol*hours/L
Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT
pmol*hours/LPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Week 6 (n=28, 31, 28)64.4 ± 74.80-26.1 ± 71.4219.5 ± 74.78
Week 24 (n=21, 25, 19)-63.3 ± 162.8180.1 ± 149.88477.0 ± 169.22
SecondaryChange From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT

The change between the AUC for C-peptide at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

Time frame:
Baseline and Weeks 6 and 24
Reported as:
Least squares mean · nmol*hours/L
Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT
nmol*hours/LPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Week 6 (n=28, 31, 28)0.051 ± 0.1779-0.091 ± 0.1696-0.138 ± 0.1780
Week 24 (n=21, 25, 19)-0.449 ± 0.23230.182 ± 0.21380.155 ± 0.2444
SecondaryChange From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT

The change between the AUC for insulin/glucose ratio at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

Time frame:
Baseline and Weeks 6 and 24
Reported as:
Least squares mean · pmol*hr/mmol
Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT
pmol*hr/mmolPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Week 6 (n=27, 29, 28)4.86 ± 5.7771.73 ± 5.578-0.75 ± 5.663
Week 24 (n=20, 23, 19)-5.36 ± 14.8231.05 ± 13.88352.68 ± 14.976
SecondaryChange From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT

The change between the AUC for glucagon at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.

Time frame:
Baseline and Weeks 6 and 24
Reported as:
Least squares mean · ng*hours/L
Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT
ng*hours/LPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Week 6 (n=27, 27, 27)-5.8 ± 9.3427.1 ± 9.390.2 ± 9.32
Week 24 (n=22, 23, 19)2.7 ± 8.5112.0 ± 8.451.0 ± 9.34

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug, for up to 28 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo QD—0/35 (0%)10/35 (28.6%)
Azilsartan Medoxomil 40 mg QD—1/35 (2.9%)10/35 (28.6%)
Azilsartan Medoxomil 80 mg QD—0/35 (0%)8/35 (22.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/351/350/35
HypoxiaRespiratory, thoracic and mediastinal disorders0/351/350/35
Most frequent other events
Most frequent other events
EventPlacebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QD
Urinary tract infectionInfections and infestations3/354/353/35
HyperglycaemiaMetabolism and nutrition disorders2/352/352/35
DiarrhoeaGastrointestinal disorders2/351/352/35
Upper respiratory tract infectionInfections and infestations2/351/352/35
ConstipationGastrointestinal disorders2/351/351/35
CholelithiasisHepatobiliary disorders0/352/350/35
CoughRespiratory, thoracic and mediastinal disorders0/352/350/35
ProteinuriaRenal and urinary disorders2/350/350/35

Baseline characteristics

Randomized Set includes all enrolled participants who were randomized via the Interactive Voice/Web Response System.

Age, Continuous
Age, Continuous(years)Placebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Mean57.1 ± 8.6654.7 ± 7.6355.8 ± 7.3755.9 ± 7.89
Age, Customized
Age, Customized(participants)Placebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
<45 years3328
Between 45 and 64 years25293084
≥65 years73313
Sex: Female, Male
Sex: Female, Male(Participants)Placebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Female14101842
Male21251763
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Hispanic or Latino11151440
Non-Hispanic or Latino24202165
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
American Indian or Alaska Native0000
Asian45211
Black or African American66719
Native Hawaiian or Other Pacific Islander0101
White25232674
Region of Enrollment
Region of Enrollment(participants)Placebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
United States353535105
Height
Height(cm)Placebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Mean169.4 ± 9.81169.8 ± 9.41167.0 ± 12.30168.8 ± 10.56
Weight
Weight(kg)Placebo QDAzilsartan Medoxomil 40 mg QDAzilsartan Medoxomil 80 mg QDTotal
Mean93.41 ± 19.16594.56 ± 20.08492.33 ± 24.02793.43 ± 21.012

10 further baseline measures are reported on the registry.

08

Study locations

68 sites
  • Birmingham, Alabama, United States
  • Green Valley, Arizona, United States
  • Tempe, Arizona, United States
  • Tucson, Arizona, United States
  • Buena Park, California, United States
  • Hawaiian Gardens, California, United States
  • Norwalk, California, United States
  • Paramount, California, United States
  • Rancho Cucamonga, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Tustin, California, United States
  • Denver, Colorado, United States
  • Bradenton, Florida, United States
  • Brooksville, Florida, United States
  • Hallandale Beach, Florida, United States
  • Jupiter, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Pembroke Pines, Florida, United States
  • St Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Winter Park, Florida, United States
  • Roswell, Georgia, United States
  • Chicago, Illinois, United States
  • Evergreen Park, Illinois, United States
  • Gurnee, Illinois, United States
  • Avon, Indiana, United States
  • Greenfield, Indiana, United States
  • Lexington, Kentucky, United States
  • Paducah, Kentucky, United States
  • Baltimore, Maryland, United States
  • Columbia, Missouri, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Margate, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Brooklyn, New York, United States
  • Calabash, North Carolina, United States
  • Greensboro, North Carolina, United States
  • Lenoir, North Carolina, United States
  • Morehead City, North Carolina, United States
  • Salisbury, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Centerville, Ohio, United States
  • Cincinnati, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Downingtown, Pennsylvania, United States
  • Fleetwood, Pennsylvania, United States
  • Reading, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Anderson, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Kingsport, Tennessee, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • Irving, Texas, United States
  • North Richland Hills, Texas, United States
  • Pearland, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Burke, Virginia, United States
  • Manassas, Virginia, United States
  • Richmond, Virginia, United States
  • Virginia Beach, Virginia, United States
  • Wauwatosa, Wisconsin, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2011
First posted
Dec 21, 2011
Start
Jan 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
May 6, 2015
Last update
May 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01496430
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 21, 2011
Start date
Jan 2012
Primary completion
May 2013
Completion
May 2013
Results posted
May 6, 2015
Last update
May 6, 2015

Study contacts

Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion